{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Regulatory-Submissions-IND-CTA-CTN”
},
“headline”: “SOP for Regulatory Submissions in Clinical Research (IND/CTA/CTN)”,
“description”: “A detailed SOP aligned with ICH GCP, WHO, and GMP guidelines for managing regulatory submissions such as IND, CTA, and CTN in global clinical trials.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}
Published on 22/12/2025
Standard Operating Procedure for Regulatory Submissions in Clinical Trials (IND/CTA/CTN)
| Department | Clinical Research |
| SOP No. | CR/REG/001/2025 |
| Supersedes | NA |
| Page No. | 1 of 22 |
| Issue Date | 26/08/2025 |
| Effective Date | 01/09/2025 |
| Review Date | 01/09/2026 |
Purpose
The purpose of this SOP is to outline the standardized process for preparing, reviewing, submitting, and tracking clinical trial regulatory submissions including Investigational New Drug (IND) applications, Clinical Trial Applications (CTA), and Clinical Trial
Scope
This SOP applies to all regulatory affairs staff, clinical research teams, investigators, and sponsors involved in the preparation and submission of clinical trial applications across global regions. It covers dossier compilation, submission formats (e.g., eCTD), timelines, communications with authorities, and documentation retention.
Responsibilities
- Regulatory Affairs Manager: Oversees the preparation and accuracy of submissions.
- Clinical Research Associate: Provides protocol-related information for submissions.
- Principal Investigator: Ensures scientific and ethical accuracy of data included in submissions.
- Quality Assurance Officer: Reviews submission documents for compliance with SOP and regulations.
- Head of Clinical Research: Approves submissions prior to dispatch.
Accountability
The Regulatory Affairs Head is accountable for ensuring all submissions comply with applicable regulations and timelines. Non-compliance may lead to regulatory delays, rejection, or penalties.
Procedure
1. Pre-Submission Preparation
Identify the type of submission required (IND, CTA, or CTN).
Collect necessary documents including Investigator’s Brochure (IB), Clinical Trial Protocol, Chemistry Manufacturing and Controls (CMC) data, and preclinical data.
Assign responsibilities to team members for document drafting, review, and compilation.
2. Compilation of Submission Dossier
Ensure all documents are formatted according to agency requirements (e.g., FDA eCTD, EMA Module 1–5).
Cross-verify data with source records and clinical trial protocol.
Include quality certificates such as Certificate of Analysis (CoA) for investigational products.
Prepare country-specific annexures as per local guidelines.
3. Review and Quality Check
QA to review the submission package against regulatory checklists.
All discrepancies must be corrected before submission.
Maintain version control for each submission document.
4. Submission to Regulatory Authority
Submit documents electronically via eCTD gateway or in paper form if required by specific agency.
Obtain electronic acknowledgment from the regulatory authority.
Ensure timelines are tracked to meet statutory deadlines.
5. Post-Submission Follow-up
Track authority queries and respond within stipulated timeframes.
Document all communications with regulatory authorities.
Maintain submission tracker for all IND/CTA/CTN filings.
6. Documentation and Archiving
Archive submission packages in Trial Master File (TMF) or eTMF.
Retain records for a minimum of 5 years post trial completion or as per local regulations.
Abbreviations
- SOP: Standard Operating Procedure
- IND: Investigational New Drug
- CTA: Clinical Trial Application
- CTN: Clinical Trial Notification
- IB: Investigator’s Brochure
- CMC: Chemistry Manufacturing and Controls
- CoA: Certificate of Analysis
- QA: Quality Assurance
- eCTD: Electronic Common Technical Document
- TMF: Trial Master File
Documents
- Submission Checklist (Annexure-1)
- Submission Tracker (Annexure-2)
- Regulatory Communication Log (Annexure-3)
References
- ICH E6(R2) Good Clinical Practice
- US FDA 21 CFR Part 312 (IND Regulations)
- EMA Clinical Trial Regulation (EU No. 536/2014)
- WHO Operational Guidelines for Ethics Committees
- CDSCO Guidance on Clinical Trials in India
Version: 1.0
Approval Section
| Prepared By | Rajesh Kumar, Regulatory Affairs Specialist |
| Checked By | Sunita Reddy, QA Officer |
| Approved By | Dr. Anil Sharma, Head of Clinical Research |
Annexures
Annexure-1: Submission Checklist
| Document | Included (Yes/No) | Remarks |
|---|---|---|
| Investigator’s Brochure | Yes | Updated version 2025 |
| Clinical Trial Protocol | Yes | Reviewed by QA |
| CMC Data | Yes | Validated |
| Informed Consent Form | Yes | EC approved |
Annexure-2: Submission Tracker
| Submission Type | Date Submitted | Authority | Status | Remarks |
|---|---|---|---|---|
| IND | 02/09/2025 | US FDA | Pending | Acknowledgment received |
| CTA | 05/09/2025 | EMA | In review | Additional data requested |
Annexure-3: Regulatory Communication Log
| Date | Authority | Query | Response | Responsible Person |
|---|---|---|---|---|
| 10/09/2025 | EMA | Clarify dosing schedule | Submitted revised protocol | Rajesh Kumar |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 26/08/2025 | 00 | Initial version | New SOP creation | Head, Clinical Research |
For more SOPs visit: Pharma SOP